RxDoctor Payments DataLook up a doctor →

Maxim Norkin, MD

Hematology · Jacksonville, FLNPI 1841428588

Payments from drug & device makers

$1,615,652in general payments, 2019–2025

Across 341 payments — averaging $4737.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$537K
  • Novartis$271K
  • ADC Therapeutics America, Inc.$235K
  • Genentech, Inc.$170K
  • Bristol Myers Squibb$116K
  • Otsuka Pharmaceutical Co., Ltd.$99K
  • plus $188K from 16 others

What the payments were for

  • Consulting fees$34,09285%
  • Speaking & faculty fees$2,7007%
  • Travel & lodging$1,8425%
  • Food & beverage$1,3103%
  • Education$1350%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,615,652 in reported general payments places this provider in the 85th percentile of 79 hematology providers in Florida.

See all hematology providers in Florida

Medicare billing

Part B allowed, 2024
$152,665
Medicare patients
465
Services billed
1,055

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PomalystPomalidomide115$2,670,912
RevlimidLenalidomide133$2,556,697
BrukinsaZanubrutinib129$1,894,827
CalquenceAcalabrutinib Maleate67$970,273
Lenalidomide63$948,072
VenclextaVenetoclax73$627,629
ScemblixAsciminib Hydrochloride24$546,208
ImbruvicaIbrutinib30$512,242
JaypircaPirtobrutinib20$509,333
SprycelDasatinib32$466,374
VyndamaxTafamidis19$465,506
JakafiRuxolitinib Phosphate29$449,804
BosulifBosutinib13$378,566
GleevecImatinib Mesylate16$159,009
PromactaEltrombopag Olamine14$118,309

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Pomalyst, Sprycel$76,944$3,137,285147 claims
Bristol Myers SquibbRevlimid$115,631$2,556,697133 claims
Beigene USA, Inc.Brukinsa$119$1,894,827129 claims
AstraZenecaCalquence$550$970,27367 claims
NovartisScemblix, Gleevec, Promacta$271,466$823,52554 claims
AbbVieVenclexta$536,711$627,62973 claims
Incyte CorporationJakafi$3,300$449,80429 claims
Taiho Oncology, Inc.Inqovi$6,139$97,96912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 79 hematology providers in Florida.

Other hematology in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →